{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.8","upperLimit":"70.7","value":"60.3"},{"groupId":"OG001","lowerLimit":"30.1","upperLimit":"51.9","value":"40.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved BOR of confirmed CR or PR according to RECIST v 1.1 by derived investigator assessment. CR: complete disappearance of all target lesions (with the exception of nodal disease) and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: \\>=30% decrease under baseline of the sum of diameters of all target measurable lesions. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, with minimum absolute increase of 5 mm for target disease or unequivocal progression of pre-existing lesions for non-target disease or any new lesion.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"Cohort 3: Arm D [EC + FOLFIRI]"},{"description":"Participants received fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W with or without bevacizumab. Bevacizumab was optional and it was given per prescribing instructions of treating physician. Participants received treatment in 28-day cycles.","id":"OG001","title":"Cohort 3: Arm E [FOLFIRI With or Without Bevacizumab]"}],"paramType":"NUMBER","populationDescription":"The FAS for Cohort 3 included all participants who were randomized in the Cohort 3 portion of the study, respectively.","reportingStatus":"POSTED","timeFrame":"From date of randomization until documented PD, or start of subsequent anticancer therapy, or death, whichever occurred first (maximum up to 14.1 months)","title":"Cohort 3: ORR by Derived Investigator Assessment - FAS","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}